Don’t miss our webinar, Navigating the Future of Cell and Gene Therapy: Financial Landscape & Market Dynamics by Disease Type, on July 25, 2024, at 2:00 PM Eastern Time. Register today by clicking HERE. Cell and gene therapy (CGT) companies continue to draw significant investments, although annual funding has decreased from over $70 billion in 2021 […]
2024 is an exciting time to be involved in the cell and gene therapy (CGT) industry. With rapid advancements in science, the industry is on the cusp of industrializing and standardizing the manufacturing and commercialization of CGT products. The future points toward standardized setups and more automated systems. However, the broad nature of the field […]
With the 2022 Cell & Gene Meeting on the Mesa (#CGMesa22) underway, here’s a look at some notable recent developments in cell and gene therapy featured in the bimonthly newsletter, Cell and Gene Therapy Business Outlook. Myrtelle, a clinical-stage gene therapy company based in Wakefield, MA, and Forge Biologics, a gene therapy contract development and […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]
Email Us: Customer Service
Phone (US): 703-778-3080
Fax: 703-778-3081
